Go to
current issue
-
A genetic framework for Alzheimer's disease prevention Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
No Abstract
-
Shedding DAYLIGHT on atrial thrombus in hyperacute stroke Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Carlos Garcia-Esperon, Mark W ParsonsNo Abstract
-
Innovative trial designs in amyotrophic lateral sclerosis: balancing efficiency and precision Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Dongsheng FanNo Abstract
-
Integrating the characterisation of traumatic brain injury Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Junfeng Feng, Zhenghui He, Jiyao JiangNo Abstract
-
The future of gene therapy for Parkinson's disease Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Roger A Barker, Philip C ButteryNo Abstract
-
Endovascular treatment of distal arterial occlusions: a more distant reality than ever? Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Raul G Nogueira, Nirav Bhatt, Diogo C Haussen, Markus A Moehlenbruch, Thanh N Nguyen, Wei HuNo Abstract
-
The International Working Group recommendations on cognitively unimpaired individuals Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Nicolas Villain, Giovanni Frisina, Howard H Feldman, Bruno DuboisNo Abstract
-
The Path-NeuroDegeneration consortium Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Elise Marsan, David Gutman, Timothy J Hohman, Mukta Phatak, Brittany N Dugger, Kate Andersh, Patrick Brannelly, John F Crary, Mike A NallsNo Abstract
-
The Curing Coma campaign in Asia-Oceania Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Gentle Sunder Shrestha, Kapil Zirpe, Masao Nagayama, Sang-Bae Ko, J Claude HemphillNo Abstract
-
Correction to Lancet Neurol 2024; 23: 1025–34 Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Belder CRS, Boche D, Nicoll JAR, et al. Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy. Lancet Neurol 2024; 23: 1025–34—In this Personal View, the x axis labels for figure 1E and F should have been 0·00, 0·25, and 0·50. This correction has been made to the online version as of May 20, 2025.
-
Simona Sacco: advancing knowledge in stroke and headache Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Udani SamarasekeraNo Abstract
-
Castellani: centrifuging CSF Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Mark WeatherallNo Abstract
-
-
Driving in people with seizures and epilepsy Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Kai Michael Schubert, Ulrich Spech, Nicholas D Lawn, Pierre Mégevand, Laura J Bonnett, Anthony G Marson, Gregory L Krauss, Marian GalovicNo Abstract
-
Natural neuroscience: rethinking brain research beyond the lab | Nachum Ulanovsky, Natural Neuroscience: Toward a Systems Neuroscience of Natural Behaviors, The MIT Press (2025), p. 302, ISBN: 978-0262044998 Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Vijay Shankar BalakrishnanNo Abstract
-
Extended CT angiography versus standard CT angiography for the detection of cardioaortic thrombus in patients with ischaemic stroke and transient ischaemic attack (DAYLIGHT): a prospective, randomised, open-label, blinded end-point trial Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Luciano A Sposato, Diana Ayan, Mobeen Ahmed, Sebastian Fridman, Jennifer L Mandzia, Maged Elrayes, Facundo Lodol, Alexander V Khaw, Lauren M Mai, Chrysi Bogiatzi, Courtney Casserly, J Alexander Fraser, Richard Chan, Anita Florendo Cumbermack, Nevena Markovic, Yeyao Yu, Derek Debicki, Lorraine Fleming, Beth Beauchamp, Lindsay Lambourn, Rodrigo BagurBackgroundCardioembolic sources often remain undetected after standard diagnostic stroke workup, contributing to high rates of recurrence. We aimed to assess whether a head-to-neck CT angiography extended at least 6 cm below the carina (extended CT angiography) can increase the detection of cardioaortic thrombi compared with standard-of-care CT angiography (standard CT angiography) in patients with
-
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
BackgroundTrehalose is a disaccharide that activates autophagy pathways in animal models of neurodegenerative diseases, with the potential to catalyse clearance of toxic, misfolded proteins in motor neurons and slow disease progression in amyotrophic lateral sclerosis (ALS). We aimed to evaluate the safety and efficacy of trehalose in individuals with ALS. MethodsThe HEALEY ALS Platform Trial is a
-
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Geoffrey T Manley, Kristen Dams-O’Connor, Michael L Alosco, Hibah O Awwad, Jeffery J Bazarian, Peter Bragge, John D Corrigan, Adele Doperalski, Adam R Ferguson, Christine L Mac Donald, David K Menon, Molly M McNett, Joukje van der Naalt, Lindsay D Nelson, Dana Pisică, Noah D Silverberg, Nsini Umoh, Lindsay Wilson, Esther L Yuh, Henrik Zetterberg, Deborah Yurgelun-ToddThe clinical severity of traumatic brain injury (TBI) is commonly classified according to the Glasgow Coma Scale (GCS) sum score as mild (13–15), moderate (9–12), or severe (3–8). A new approach is needed for characterising TBI more accurately. In 2022, the US National Institutes of Health–National Institute of Neurological Disorders and Stroke launched an international initiative to address this need
-
Protective genetic variants against Alzheimer's disease Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Claudia Marino, Vincent Malotaux, Averi Giudicessi, David Aguillon, Diego Sepulveda-Falla, Francisco Lopera, Yakeel T QuirozGenetic studies can offer powerful insights for the development of disease-modifying therapies for Alzheimer's disease. Protective genetic variants that delay the onset of cognitive impairment have been found in people with sporadic Alzheimer's disease and in carriers of mutations that usually cause autosomal-dominant Alzheimer's disease in mid-life. The study of families who carry autosomal dominant
-
CSF transport at the brain–meningeal border: effects on neurological health and disease Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Liliana M Pinho-Correia, Samuel J C McCullough, Hashmat Ghanizada, Maiken Nedergaard, Justin Rustenhoven, Sandro Da MesquitaThe existence of specialised structures that allow a continuous exchange of CSF between different anatomical compartments at the brain–meningeal border is challenging conventional notions around molecular transport within the brain. Experimental findings highlight the conduits and cellular structures controlling the transport of CSF and immune cells between the brain parenchyma (via the glymphatic
-
Gene therapy for Parkinson's disease: trials and technical advances Lancet Neurol. (IF 46.5) Pub Date : 2025-05-20
Graham Winston, Natasha Kharas, Per Svenningsson, Ashwani Jha, Michael G KaplittGene therapy has long held promise as a method for targeted alteration of neuronal function in Parkinson's disease. Different gene-therapy approaches aim to correct dysfunctional circuits or have attempted to protect vulnerable neurons to slow disease progression. Clinical trials have used viral vectors to deliver genes either directly into brain regions through stereotaxic injection or globally through
-
Correction to Lancet Neurol 2025; 24: 279–81 Lancet Neurol. (IF 46.5) Pub Date : 2025-04-17
Schott JM. Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time? Lancet Neurol 2025; 24: 279–81—In this Comment, the analyses of 22 asymptomatic individuals has been changed to prespecified in paragraph seven. This correction has been made to the online version as of April 17, 2025.
-
AI and neurology: an ethical path to innovation Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
The Lancet NeurologyNo Abstract
-
Carotid revascularisation for carotid stenosis Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Jan K Ho, Graeme J HankeyNo Abstract
-
Neuropathic pain: which treatment for which patient? Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Claudia SommerNo Abstract
-
CGRP blockade and cluster headache: another step forward Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Elizabeth LerouxNo Abstract
-
Temporal and biological heterogeneity in Lewy body disease Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Afina W Lemstra, Wilma D J van de BergNo Abstract
-
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Dame Pamela ShawNo Abstract
-
Prioritising faster, individualised rescue treatment in status epilepticus Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Nathalia Penagos Vargas, Oscar Mauricio Espitia SeguraNo Abstract
-
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Jennifer V Gettings, Fatemeh Mohammad Alizadeh Chafjiri, Tobias LoddenkemperNo Abstract
-
Neurology cannot be embedded in non-communicable disease agendas Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Matilde Leonardi, Elena Moro, Paul Boon, Kailash P Bhatia, Claudio Bassetti, Alberto RaggiNo Abstract
-
Correction to Lancet Neurol 2024; 23: 500–10 Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Wisch JK, McKay NS, Boerwinkle AH, et al. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol 2024; 23: 500–10—In this Article, the colours in the key for parts D, E, and F of figure 3 have been swapped, and the labels for the vertical lines in figure 3D have been swapped. These corrections have been made to the
-
Correction to Lancet Neurol 2025; 24: 290 Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Drouin E, Tatu L, Hautecoeur P. Augusta Dejerine-Klumpke, a neurologist ahead of her time. Lancet Neurol 2025; 24: 290—In this Focal Point, the spelling of author Patrick Hautecoeur's name was incorrect. This correction has been made to the online version as of April 16, 2025.
-
Margaret Pericak-Vance: a force of nature in human genetics Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Jules MorganNo Abstract
-
-
-
Would you want to know if you had Alzheimer's disease? Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Peter RanscombeNo Abstract
-
Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Simone J A Donners MD, Twan J van Velzen PhD, Suk Fun Cheng PhD, John Gregson PhD, Audinga-Dea Hazewinkel PhD, Francesca B Pizzini PhD, Bart J Emmer PhD, Robert Simister PhD, Prof Toby Richards FRCS, Philippe A Lyrer MD, Marina Maurer MD, Gemma Smith MBBS, Gareth Tervit FRCSEd, Laurine van der Steen MSc, Prof Gwynedd E Pickett MD, Prof Gordon Gubitz FRCPC, Prof Bob Roozenbeek PhD, Maaike Scheele, JohnCarotid revascularisation, comprising either carotid endarterectomy or stenting, is offered to patients with carotid stenosis to prevent stroke based on the results of randomised trials conducted more than 30 years ago. Since then, medical therapy for stroke prevention has improved. We aimed to assess whether patients with asymptomatic and symptomatic carotid stenosis with a low or intermediate predicted
-
Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Nadia Soliman PhD, Prof Xavier Moisset MD, Michael C Ferraro BSc, Daniel Ciampi de Andrade MD, Ralf Baron MD, Joletta Belton MSc, Prof David L H Bennett PhD, Margarita Calvo MD, Prof Patrick Dougherty PhD, Prof Ian Gilron MD, Aki J Hietaharju MD, Koichi Hosomi MD, Prof Peter R Kamerman PhD, Harriet Kemp MD, Prof Elena K Enax-Krumova MD, Ewan McNicol MS, Prof Theodore J Price PhD, Prof Srinivasa N RajaThere remains a substantial unmet need for effective and safe treatments for neuropathic pain. The Neuropathic Pain Special Interest Group aimed to update treatment recommendations, published in 2015, on the basis of new evidence from randomised controlled trials, emerging neuromodulation techniques, and advances in evidence synthesis.
-
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Prof Cristina Tassorelli MD PhD, Prof Rigmor H Jensen DrMedSci, Prof Peter J Goadsby MD, Prof Andrew C Charles MD, Prof Stewart J Tepper MD, Agneta Henriette Snoer MD PhD, Mette Krog Josiassen PhD, Christine Borgen Linander PhD, Anders Ettrup PhD, Bjørn Sperling MD, Neli Boneva MD PhDChronic cluster headache is an uncommon but highly debilitating primary headache disorder characterised by excruciating head pain recurring in daily attacks and without remission periods longer than 3 months. Treatment is challenging due to the few strategies available. Eptinezumab, approved for migraine prevention, is a humanised monoclonal antibody that targets calcitonin gene-related peptide, which
-
Biological effects of pathologies in Lewy body diseases: why timing matters Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Elie Matar MD PhD, Prof Glenda M Halliday PhDThe emergence of promising biomarkers of α-synuclein Lewy pathology has led to new biological definitions and staging systems for Parkinson's disease and dementia with Lewy bodies. These research frameworks aim to enhance patient selection for studies of biomarkers and disease-modifying therapies. Building on approaches developed for Alzheimer's disease, these new frameworks focus on hallmark neuropathological
-
Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy Lancet Neurol. (IF 46.5) Pub Date : 2025-04-16
Rubika Balendra MRCP PhD, Jemeen Sreedharan MRCP PhD, Martina Hallegger PhD, Raphaëlle Luisier PhD, Prof Hilal A Lashuel PhD, Prof Jenna M Gregory MB PhD, Prof Rickie Patani FRCP PhDMutations in the TARDBP gene, which encodes the TDP-43 protein, account for only 3–5% of familial cases of amyotrophic lateral sclerosis and less than 1% of cases that are apparently idiopathic. However, the discovery of neuronal inclusions of TDP-43 as the neuropathological hallmark in the majority of cases of amyotrophic lateral sclerosis has transformed our understanding of the pathomechanisms underlying
-
Rehabilitation drives post-stroke motor recovery Lancet Neurol. (IF 46.5) Pub Date : 2025-03-26
Teresa J Kimberley, Ela B PlowNo Abstract
-
Fraud, arrogance, and tragedy: the case of Doctored Lancet Neurol. (IF 46.5) Pub Date : 2025-03-26
John HardyNo Abstract
-
Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trial Lancet Neurol. (IF 46.5) Pub Date : 2025-03-26
Prof Gottfried Schlaug MD, Christy Cassarly PhD, Jody A Feld PhD, Prof Steve L Wolf PhD, Veronica T Rowe PhD, Prof Stacy Fritz PhD, Pratik Y Chhatbar PhD, Anant Shinde PhD, Zemin Su MAS, Prof Joseph P Broderick MD, Prof Richard Zorowitz MD, Oluwole Awosika MD, Prof Dylan Edwards PhD, Chen Lin MD, Prof Gerard E Franciso MD, Prof George F Wittenberg MD, Prof Svetlana Pundik MD, Prof Christopher GregoryMotor impairments contribute substantially to long-term disability following stroke. Studies of transcranial direct current stimulation (tDCS), combined with various rehabilitation therapies, have shown promising results in reducing motor impairment. We aimed to evaluate the safety and efficacy of three doses of tDCS in combination with modified constraint-induced movement therapy (mCIMT) in people
-
Correction to Lancet Neurol 2024; 23: 1013–24 Lancet Neurol. (IF 46.5) Pub Date : 2025-03-25
Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2024; 23: 1013–24—In this Article, corrections have been made to definitions of safety populations in tables 1 and 3,
-
Advancing policies for rare diseases in Europe Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
The Lancet NeurologyNo Abstract
-
Pharmacological therapy for cerebral cavernous malformations Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Rustam Al-Shahi Salman, Michael J ThrippletonNo Abstract
-
Thrombolysis before endovascular treatment of tandem lesions Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Bertrand Lapergue, Benjamin GoryNo Abstract
-
Amyloid immunotherapy to prevent Alzheimer's disease: the wrong drug at the right time? Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Jonathan M SchottNo Abstract
-
SARS-CoV-2 infection in people with multiple sclerosis Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Kathryn C FitzgeraldNo Abstract
-
Uncontrolled CAG expansion in neurons susceptible to Huntington's disease Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Alexandra DurrNo Abstract
-
The Genetic Epidemiology of Parkinson's Disease view Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Matthew J Farrer, GEoPD, Rosanna Asselta, Jean-Christophe Corvol, David Crosiers, Alexis Elbaz, Matthew J. Farrer, Alessio Di Fonzo, Nobutaka Hattori, Beomseok Jeon, Rejko Krüger, George Mellick, Katerina Markopoulou, Manu Sharma, Karin WirdefeldtNo Abstract
-
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Shen-Yang Lim, all the authors, Ai Huey Tan, Azlina Ahmad-Annuar, Njideka Ulunma Okubadejo, Katja Lohmann, Huw R Morris, Tzi Shin Toh, Yi Wen Tay, Lara M Lange, Sara Bandres-Ciga, Ignacio Mata, Jia Nee Foo, Esther Sammler, Joshua Chin Ern Ooi, Alastair J Noyce, Natascha Bahr, Wei Luo, Rajeev Ojha, Andrew B Singleton, Cornelis Blauwendraat, Christine KleinNo Abstract
-
Raising awareness of degenerative cervical myelopathy Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Jay John Wardropper, Andreas K Demetriades, David B AndersonNo Abstract
-
Paediatric neurology in Ukraine: a call for help Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Alla Nechai, Oxana Nazar, Kevin Rostasy, Sameer M Zuberi, Dana Craiu, Anna Jansen, Coriene E Catsman-BerrevoetsNo Abstract
-
Advocating for increased awareness and research on Down syndrome Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Marie-Claude Potier, Trisomy 21 Research Society executive board, Pierce Jonathan, Hilgenkamp Thessa, Stagni Fiorenza, Emili Marco, Wiseman Frances, Ropper Randall, Carmona-Iragui María, Rebillat Anne-Sophie, Barone Eugenio, Perluigi Marzia, Skotko Brian, Zaman Shahid, Sullivan Kelly, Rozen Esteban, Granholm-Bentley Ann-Charlotte, Bartesaghi Renata, Mobley William, Delabar Jean-Maurice, Dierssen MaraNo Abstract
-
-
Augusta Dejerine-Klumpke, a neurologist ahead of her time Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Emmanuel Drouin, Laurent Tatu, Patrick HautecoeurNo Abstract
-
An operational measurement of brain health: the ABCDS framework Lancet Neurol. (IF 46.5) Pub Date : 2025-03-19
Abolfazl Avan, Robert Andersen, Neil Andersson, Stephanie J Frisbee, Sarah Singh, Shiran Zhong, Kem A Rogers, Shawn N Whitehead, Vladimir HachinskiNo Abstract
更新日期：2025-04-16
Copyright © 2014-2025 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号